INTRODUCTION Inhibitory sensory gating of the P50 cerebral evoked potential to paired auditory stimuli (S1, S2) is a widely used paradigm for the study of schizophrenia and related conditions. Its use to measure genetic, treatment, and developmental effects requires a metric with more stable properties than the simple ratio of the paired responses. METHODS This study assessed the ratio P50S2μV/P50S1μV and P50S2μV co-varied for P50S1μV in all 27 independent published studies that compared schizophrenia patients with healthy controls from 2000 to 2019. The largest study from each research group was selected. The Colorado research group's studies were excluded to eliminate bias from the first report of the phenomenon. RESULTS Across the 27 studies encompassing 1179 schizophrenia patients and 1091 healthy controls, both P50S2μV co-varied for P50S1μV and P50S2μV/P50S1μV significantly separated the patients from the controls (both P < 0.0001). Effect size for P50S2μV co-varied for P50S1μV is d' = 1.23. The normal distribution of P50S2μV co-varied for P50S1μV detected influences of maternal inflammation and effects on behavior in a recent developmental study, an emerging use for the P50 inhibitory gating measure. P50S2μV/P50S1μV was not normally distributed. Results from two multi-site NIMH genetics collaborations also support the use of P50S2μV as a biomarker. CONCLUSION Both methods detect an abnormality of cerebral inhibition in schizophrenia with high significance across multiple independent laboratories. The normal distribution of P50S2μV co-varied for P50S1μV makes it more suitable for studies of genetic, treatment, and other influences on the development and expression of inhibitory deficits in schizophrenia.

中文翻译：

---

精神分裂症中的 P50 抑制性感觉门控：近期研究分析

介绍 P50 大脑诱发电位对成对听觉刺激（S1、S2）的抑制性感觉门控是研究精神分裂症和相关疾病的广泛使用的范例。它用于测量遗传、治疗和发育影响需要一个具有比配对反应的简单比率更稳定特性的指标。方法 本研究评估了所有 27 项独立发表的研究中 P50S1μV 的 P50S2μV/P50S1μV 和 P50S2μV 的共变比率，这些研究比较了 2000 年至 2019 年间精神分裂症患者与健康对照者。选择了每个研究组中最大的研究。科罗拉多研究小组的研究被排除在外，以消除对该现象的第一份报告的偏见。结果 在包括 1179 名精神分裂症患者和 1091 名健康对照者的 27 项研究中，P50S1μV 和 P50S2μV/P50S1μV 的 P50S2μV 共变显着将患者与对照组分开（均 P < 0.0001）。P50S2μV 的效应大小随 P50S1μV 共同变化为 d' = 1.23。P50S2μV 的正态分布随 P50S1μV 共同变化，在最近的一项发育研究中检测到母体炎症的影响和对行为的影响，这是 P50 抑制门控措施的新兴用途。P50S2μV/P50S1μV 不是正态分布的。两个多站点 NIMH 遗传学合作的结果也支持使用 P50S2μV 作为生物标志物。结论这两种方法都检测到精神分裂症的脑抑制异常，在多个独立实验室中具有很高的意义。P50S2μV 与 P50S1μV 共变的正态分布使其更适合遗传、治疗、